Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.62 +0.42 (+0.63%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
59 60 Next >
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
Third COVID-19 Booster or Fifth Dose Not Required Despite Surge In Cases, Australian Health Authorities Say
Australian health authorities have recommended against a fifth COVID-19 vaccine shot despite average daily cases having been 47% higher last week than the week before, said Health Minister Mark Butler... 
Via Benzinga
Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina
Rosenblatt boosted the price target on Amazon.com, Inc. (NASDAQ: AMZN) from $118 to $103. Rosenblatt analyst Barton Crockett maintained the stock with a Neutral rating. Amazon shares fell 4.3% to close... 
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Via Benzinga
AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript
AZN earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Why AstraZeneca Stock Shot Higher Today
The company trounced analyst profitability estimates for its latest quarter and raised its guidance. 
Via The Motley Fool
Why Are Apellis Pharmaceuticals Shares Falling Today?
Via Benzinga
FDA Approves AstraZeneca's Imfinzi/Imjudo Chemo Combo For Late Stage Lung Cancer
Via Benzinga
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
Repeat COVID-19 Infection Increases Risk Of Acute Outcomes, Long COVID Symptoms, Study Shows
Via Benzinga
AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth
Excluding exchange rates, AstraZeneca's sales surged 19% and came in above forecasts. 
Via Investor's Business Daily
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
From AstraZeneca
Via Business Wire
Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday
The company released encouraging year-end guidance. 
Via The Motley Fool
Troubled FTX Faces SEC Probe And 'Urgently Needs' $8B To Avoid Bankruptcy, NIO Posts Wider Q3 Loss, AstraZeneca Ditches US Application Submission For COVID-19 Shot: Top Stories Thursday, Nov. 11
Bloomberg 
Via Benzinga
Apple Hires Facebook Veteran as Information Chief; More Departures Likely
Via Benzinga
Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend Stocks
These stocks both pay more than 2% per year in dividends. 
Via The Motley Fool
AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength
Via Benzinga
'Waiting Game Continues' In Emergent BioSolutions, Analysts Cut Price Target
Via Benzinga
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
Via Benzinga
Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022
On CNBC's "Options Action," Michael Khouw of Optimize Advisors said that AstraZeneca plc. (NASDAQ: AZN) traded 3.9 times its average daily put volume on Tuesday. 
Via Benzinga
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
From AstraZeneca
Via Business Wire
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Via Benzinga
Sorrento Has Potential To Deliver Multiple Best-In-Class Products
Via Benzinga
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.
As the Fed continues to tighten the market, consider putting these seven on your list of overvalued Nasdaq stocks to sell before 2022 ends. 
Via InvestorPlace
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
European Regulator Grants Complete Approval To AstraZeneca's COVID-19 Vaccine
Via Benzinga
15 Global Psychedelics Executives To Keep An Eye On In 2022
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list... 
Via Benzinga
Why Invitae Stock Was So Healthy This Week
Even though the genetics testing specialist didn't divulge the financial details of a new partnership, investors nevertheless were happpy about the news. 
Via The Motley Fool
Ranking 7 Top Tech Stocks to Buy From Biggest to Smallest
Although "Big Tech" is currently struggling, but there are still many good top tech stocks to buy at this point. 
Via InvestorPlace
3 Perfect Stocks Retirees Can Buy Hand Over Fist Right Now
Bargains abound for seniors who want steady long-term appreciation potential. 
Via The Motley Fool
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS